The first study for such a combination approach was published by Hemminki and his team in 2012, demonstrating that targeted cancer immunotherapy could be achieved using an oncolytic AdV encoding a fully humanized monoclonal Ab reactive against CTLA-4 (108). The gene discussed is CTLA4; the disease is cancer.